Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Kodiak Sciences Inc stock faces analyst scrutiny amid biotech pipeline delays and hold consensus
Kodiak Sciences Inc (KOD) is facing analyst scrutiny due to pipeline delays in its lead asset, tarcocimab tedromer, for wet AMD, resulting in a consensus “Hold” rating. Investors are closely watching for Phase 3 trial readouts, which have been repeatedly delayed, pushing key catalysts into 2026. While the company maintains a cash position to support operations through late 2026, concerns remain regarding execution risks, competition, and potential capital raises for market launch.